15,250 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,250 shares of the company’s stock, valued at approximately $121,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Geode Capital Management LLC increased its holdings in Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. State Street Corp increased its holdings in Amneal Pharmaceuticals by 3.8% in the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after purchasing an additional 127,753 shares in the last quarter. Hennessy Advisors Inc. increased its holdings in Amneal Pharmaceuticals by 6.8% in the 4th quarter. Hennessy Advisors Inc. now owns 1,670,600 shares of the company’s stock worth $13,231,000 after purchasing an additional 106,600 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Amneal Pharmaceuticals by 16.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock worth $11,689,000 after purchasing an additional 202,863 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after purchasing an additional 777,568 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Piper Sandler upped their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of AMRX stock opened at $7.91 on Friday. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -11.63 and a beta of 1.10. The stock has a 50-day moving average of $8.09 and a 200-day moving average of $8.25. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48.

Insider Activity

In other news, Director Gautam Patel sold 62,590 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 160,000 shares of company stock valued at $1,292,000. Company insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.